Clinical Trial Update: Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating tadalafil in combination with pembrolizumab in recurrent or metastatic head and neck cancer has completed enrollment and posted results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• TADALAFIL (TADALAFIL)

Snippet

Sponsor: University of California, San Diego | Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2026-02-12